Stay updated on Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries.
    Difference
    34%
    Check dated 2025-08-30T11:43:36.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.3%
    Check dated 2025-08-16T04:38:43.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.3%
    Check dated 2025-08-08T23:54:07.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a service alert regarding planned maintenance has been removed.
    Difference
    4%
    Check dated 2025-08-01T19:27:19.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.
    Difference
    0.8%
    Check dated 2025-07-25T14:50:32.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.5 to version 2.16.6.
    Difference
    0.3%
    Check dated 2025-07-18T11:35:06.000Z thumbnail image

Stay in the know with updates to Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.